- Home
- BNR vs HHS Comparison
BNR vs HHS Comparison
Compare BNR & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- HHS
- Stock Information
- Founded
- BNR 2014
- HHS 1923
- Country
- BNR China
- HHS United States
- Employees
- BNR N/A
- HHS N/A
- Industry
- BNR Medical Specialities
- HHS Advertising
- Sector
- BNR Health Care
- HHS Consumer Discretionary
- Exchange
- BNR Nasdaq
- HHS Nasdaq
- Market Cap
- BNR 38.3M
- HHS 28.4M
- IPO Year
- BNR 2020
- HHS N/A
- Fundamental
- Price
- BNR $6.47
- HHS $3.29
- Analyst Decision
- BNR
- HHS
- Analyst Count
- BNR 0
- HHS 0
- Target Price
- BNR N/A
- HHS N/A
- AVG Volume (30 Days)
- BNR 53.8K
- HHS 8.0K
- Earning Date
- BNR 08-21-2025
- HHS 08-07-2025
- Dividend Yield
- BNR N/A
- HHS N/A
- EPS Growth
- BNR N/A
- HHS N/A
- EPS
- BNR N/A
- HHS N/A
- Revenue
- BNR $72,112,038.00
- HHS $181,355,000.00
- Revenue This Year
- BNR $136.32
- HHS $6.54
- Revenue Next Year
- BNR N/A
- HHS N/A
- P/E Ratio
- BNR N/A
- HHS N/A
- Revenue Growth
- BNR 0.53
- HHS N/A
- 52 Week Low
- BNR $2.18
- HHS $3.06
- 52 Week High
- BNR $9.48
- HHS $8.49
- Technical
- Relative Strength Index (RSI)
- BNR 60.79
- HHS 36.41
- Support Level
- BNR $5.81
- HHS $3.20
- Resistance Level
- BNR $9.48
- HHS $3.55
- Average True Range (ATR)
- BNR 0.90
- HHS 0.24
- MACD
- BNR 0.12
- HHS 0.01
- Stochastic Oscillator
- BNR 45.86
- HHS 23.71
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.